Lam Dong Pharmaceutical addresses stock warning with turnaround plan

Lam Dong Pharmaceutical's stock is under warning due to negative retained earnings and audit issues related to accounts receivable from Bao Thu Industrial Development and Investment JSC.

The company reported consolidated after-tax profit of VND 6.9 billion in 2024. First-half 2025 revenue increased 19.45% with pre-tax profit up 15.5%.

Recovery measures include boosting core business, controlling costs, and capital increases through employee stock options and private placement.